This company has been marked as potentially delisted and may not be actively trading. NantKwest (NK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NK vs. PRME, PLX, IKT, IZTC, CVM, ZIVO, CRTX, JATT, ALVR, and FNCHShould you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector. NantKwest vs. Its Competitors Prime Medicine Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group Prime Medicine (NYSE:PRME) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Is PRME or NK more profitable? Prime Medicine has a net margin of 0.00% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% NantKwest -76,658.58%-56.06%-46.93% Do institutionals and insiders believe in PRME or NK? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, PRME or NK? Prime Medicine has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500. Do analysts recommend PRME or NK? Prime Medicine presently has a consensus price target of $8.92, suggesting a potential upside of 119.08%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts plainly believe Prime Medicine is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, PRME or NK? NantKwest has lower revenue, but higher earnings than Prime Medicine. NantKwest is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$4.96M110.40-$198.13M-$1.56-2.61NantKwest$40K7,107.43-$65.79M-$0.70-3.71 Does the media refer more to PRME or NK? In the previous week, Prime Medicine had 3 more articles in the media than NantKwest. MarketBeat recorded 3 mentions for Prime Medicine and 0 mentions for NantKwest. Prime Medicine's average media sentiment score of 0.26 beat NantKwest's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Neutral NantKwest Neutral SummaryPrime Medicine beats NantKwest on 10 of the 17 factors compared between the two stocks. Get NantKwest News Delivered to You Automatically Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NK vs. The Competition Export to ExcelMetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$284.30M$289.72M$5.85B$10.14BDividend YieldN/AN/A5.68%4.60%P/E Ratio-3.66N/A75.3425.98Price / Sales7,107.43420.31514.55181.19Price / CashN/A22.4437.5660.44Price / Book2.1110.9112.156.29Net Income-$65.79M-$111.61M$3.29B$271.07M NantKwest Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKNantKwestN/A$2.60+0.4%N/A-28.5%$284.30M$40K-3.66160High Trading VolumePRMEPrime Medicine3.2911 of 5 stars$4.12+5.9%$8.92+116.4%+0.5%$554.45M$4.96M-2.01234PLXProtalix BioTherapeutics2.3353 of 5 stars$1.72+8.9%$15.00+772.1%+70.8%$137.14M$61.95M-13.23200IKTInhibikase Therapeutics1.4723 of 5 stars$1.67+0.6%$6.50+289.2%+30.0%$124.44MN/A-0.636IZTCInvizyne TechnologiesN/A$12.00+0.3%N/AN/A$75.02MN/A0.0029News CoverageGap DownCVMCEL-SCI1.347 of 5 stars$10.69+3.3%N/A-71.5%$73.57MN/A-22.2743Positive NewsShort Interest ↓ZIVOZIVO Bioscience0.3545 of 5 stars$13.50-9.1%N/A-3.7%$51.53M$15.85K-2.7710News CoverageHigh Trading VolumeCRTXCortexymeN/A$1.57-2.5%N/A+115.0%$47.34MN/A-0.5355JATTJATT AcquisitionN/A$2.21+0.5%N/A-42.3%$38.12MN/A0.003News CoverageHigh Trading VolumeALVRAlloVirN/A$4.64+0.4%N/A-75.2%$23.40MN/A-0.23110Gap DownHigh Trading VolumeFNCHFinch Therapeutics Group1.407 of 5 stars$12.67-0.2%N/A+6.3%$20.35MN/A-1.44190Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies PRME Alternatives PLX Alternatives IKT Alternatives IZTC Alternatives CVM Alternatives ZIVO Alternatives CRTX Alternatives JATT Alternatives ALVR Alternatives FNCH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NK) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
